ValuEngine lowered shares of Rigel Pharmaceuticals (NASDAQ:RIGL) from a hold rating to a sell rating in a research report report published on Friday.

A number of other analysts have also recently weighed in on RIGL. Jefferies Group reissued a buy rating and issued a $5.00 target price on shares of Rigel Pharmaceuticals in a research note on Tuesday, September 5th. Zacks Investment Research raised shares of Rigel Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, September 20th. BMO Capital Markets reissued a buy rating and issued a $5.00 target price on shares of Rigel Pharmaceuticals in a research note on Monday, October 2nd. HC Wainwright reissued a buy rating and issued a $7.00 target price on shares of Rigel Pharmaceuticals in a research note on Monday, November 6th. Finally, Cantor Fitzgerald started coverage on shares of Rigel Pharmaceuticals in a research note on Thursday, December 14th. They issued an overweight rating and a $6.00 target price on the stock. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $5.45.

Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) opened at $3.41 on Friday. Rigel Pharmaceuticals has a 52 week low of $1.94 and a 52 week high of $4.47.

Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. The business had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals had a negative net margin of 354.14% and a negative return on equity of 102.26%. The business’s revenue was down 76.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.24) EPS. analysts expect that Rigel Pharmaceuticals will post -0.56 earnings per share for the current fiscal year.

In other Rigel Pharmaceuticals news, CFO Ryan D. Maynard sold 100,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $3.90, for a total transaction of $390,000.00. Following the sale, the chief financial officer now directly owns 100,000 shares of the company’s stock, valued at $390,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.21% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the business. AXA bought a new stake in Rigel Pharmaceuticals during the second quarter worth about $122,000. Voya Investment Management LLC grew its stake in Rigel Pharmaceuticals by 30.4% during the second quarter. Voya Investment Management LLC now owns 53,661 shares of the biotechnology company’s stock worth $146,000 after buying an additional 12,500 shares during the last quarter. SG Americas Securities LLC grew its stake in Rigel Pharmaceuticals by 415.2% during the third quarter. SG Americas Securities LLC now owns 59,401 shares of the biotechnology company’s stock worth $151,000 after buying an additional 47,872 shares during the last quarter. Engineers Gate Manager LP bought a new stake in Rigel Pharmaceuticals during the second quarter worth about $193,000. Finally, State of Wisconsin Investment Board bought a new stake in Rigel Pharmaceuticals during the second quarter worth about $232,000. 74.51% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/valuengine-downgrades-rigel-pharmaceuticals-rigl-to-sell/1772288.html.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.